Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 1.5%

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) fell 1.5% during trading on Thursday . The stock traded as low as $11.57 and last traded at $12.07. 83,451 shares changed hands during trading, a decline of 19% from the average session volume of 102,474 shares. The stock had previously closed at $12.26.

Lexeo Therapeutics Stock Performance

The business has a 50 day moving average of $14.62. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.21 and a quick ratio of 7.21.

Lexeo Therapeutics (NASDAQ:LXEO) last released its earnings results on Monday, March 11th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.15). Analysts forecast that Lexeo Therapeutics, Inc. will post -3.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of hedge funds have recently added to or reduced their stakes in LXEO. Eventide Asset Management LLC acquired a new stake in Lexeo Therapeutics in the fourth quarter valued at approximately $40,298,000. Omega Fund Management LLC acquired a new stake in Lexeo Therapeutics in the fourth quarter valued at approximately $28,955,000. Citadel Advisors LLC acquired a new stake in Lexeo Therapeutics in the fourth quarter valued at approximately $27,971,000. Novo Holdings A S acquired a new stake in Lexeo Therapeutics in the fourth quarter valued at approximately $17,551,000. Finally, Blackstone Inc. acquired a new stake in Lexeo Therapeutics in the fourth quarter valued at approximately $9,342,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.